IP Library › Granted Patent US 12,642,851
Granted Patent B2
US 12,642,851 · App. 19/067,426 · Granted Jun 2, 2026

Self-assembling nanoparticles

Inventors: Geoffrey Martin Lynn (Baltimore, MD); Christopher Martin O'Brien Garliss (Baltimore, MD); Andrew Scott Ishizuka (Washington, DC); Hugh Clarke Welles (Baltimore, MD)
Assignees: Barinthus Biotherapeutics North America, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Services
A61K39/385A61K39/35A61K47/545A61K47/549A61K47/646A61K47/6935A61P3/10A61P37/06A61K2039/54A61K2039/577A61K2039/6093
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,642,851
App. No.
19/067,426
Granted
Jun 2, 2026
Kind
B2
Abstract

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]-H and H-[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

Claims (223)

1 . A compound of Formula (1):

wherein

 is an antigen (A), wherein each R 8 is independently an amino acid side chain, and a is an integer number of amino acids, and

wherein A comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 464)

QGIIQPEQPAQLEVI,

(SEQ ID NO: 486)

QLQPFPQPELPYPQPQLPYPQPQPFR,

(SEQ ID NO: 487)

PQLPYPQPELPYPQPQPFRPEQPYPQPQP,

(SEQ ID NO: 488)

PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,

(SEQ ID NO: 489)

PQQPFPQPEQPFCQQPQ,

(SEQ ID NO: 490)

QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,

(SEQ ID NO: 491)

QQFSQPEQEFPQPQQPQQSFPEQQPPF,

(SEQ ID NO: 492)

PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ,

(SEQ ID NO: 493)

SSPLQPEQPFPQQPQQPFPEQPQQPQ,

(SEQ ID NO: 494)

QSIPQPEQPFPQPEQPFPQSQE,

(SEQ ID NO: 495)

PQQPFPQQPQQIIPQ,

(SEQ ID NO: 496)

PQQPIPEQPQPYPEQPQPYPQQ, 

and

(SEQ ID NO: 497)

PQQPFPQPEQPFBQQPQ, wherein B represents 

alpha-aminobutyric acid,

2 . The compound of claim 1 , wherein A comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 486)

QLQPFPQPELPYPQPQLPYPQPQPFR,

(SEQ ID NO: 487)

PQLPYPQPELPYPQPQPFRPEQPYPQPQP,

(SEQ ID NO: 488)

PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,

(SEQ ID NO: 490)

QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,

(SEQ ID NO: 491)

QQFSQPEQEFPQPQQPQQSFPEQQPPF,

(SEQ ID NO: 492)

PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ,

(SEQ ID NO: 493)

SSPLQPEQPFPQQPQQPFPEQPQQPQ,

(SEQ ID NO: 494)

QSIPQPEQPFPQPEQPFPQSQE,

(SEQ ID NO: 495)

PQQPFPQQPQQIIPQ,

(SEQ ID NO: 496)

PQQPIPEQPQPYPEQPQPYPQQ, 

and

(SEQ ID NO: 497)

PQQPFPQPEQPFBQQPQ,

wherein B represents alpha-aminobutyric acid.

3 . The compound of claim 2 , wherein A comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 486)

QLQPFPQPELPYPQPQLPYPQPQPFR,

(SEQ ID NO: 487)

PQLPYPQPELPYPQPQPFRPEQPYPQPQP,

(SEQ ID NO: 488)

PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,

(SEQ ID NO: 490)

QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,

(SEQ ID NO: 491)

QQFSQPEQEFPQPQQPQQSFPEQQPPF,

(SEQ ID NO: 493)

SSPLQPEQPFPQQPQQPFPEQPQQPQ,

(SEQ ID NO: 494)

QSIPQPEQPFPQPEQPFPQSQE,

(SEQ ID NO: 495)

PQQPFPQQPQQIIPQ,

(SEQ ID NO: 496)

PQQPIPEQPQPYPEQPQPYPQQ, 

and

(SEQ ID NO: 497)

PQQPFPQPEQPFBQQPQ, 

wherein B represents alpha-aminobutyric acid.

4 . A composition comprising a compound of claim 1 , and optionally further comprising a compound of Formula (1) wherein A comprises an amino acid sequence selected from QQPPFSEQEQPVLPQ (SEQ ID NO:484) or QPPFSQQQESPFSQQ (SEQ ID NO: 485).

5 . A composition comprising a compound of Formula (1):

wherein

 is an antigen (A), wherein each R 8 is independently an amino acid side chain, and a is an integer number of amino acids,

wherein A comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 464)

QGIIQPEQPAQLEVI,

(SEQ ID NO: 484)

QQPPFSEQEQPVLPQ,

(SEQ ID NO: 486)

QLQPFPQPELPYPQPQLPYPQPQPFR,

(SEQ ID NO: 487)

PQLPYPQPELPYPQPQPFRPEQPYPQPQP,

(SEQ ID NO: 488)

PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,

(SEQ ID NO: 489)

PQQPFPQPEQPFCQQPQ,

(SEQ ID NO: 490)

QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,

(SEQ ID NO: 491)

QQFSQPEQEFPQPQQPQQSFPEQQPPF,

(SEQ ID NO: 492)

PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ,

(SEQ ID NO: 493)

SSPLQPEQPFPQQPQQPFPEQPQQPQ,

(SEQ ID NO: 494)

QSIPQPEQPFPQPEQPFPQSQE,

(SEQ ID NO: 495)

PQQPFPQQPQQIIPQ,

(SEQ ID NO: 496)

PQQPIPEQPQPYPEQPQPYPQQ, 

and

(SEQ ID NO: 497)

PQQPFPQPEQPFBQQPQ, 

wherein B represents alpha-aminobutyric acid,

 and wherein the composition comprises two or more unique compounds of Formula (1).

6 . The composition of claim 5 , wherein A comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 484)

QQPPFSEQEQPVLPQ,

(SEQ ID NO: 486)

QLQPFPQPELPYPQPQLPYPQPQPFR,

(SEQ ID NO: 487)

PQLPYPQPELPYPQPQPFRPEQPYPQPQP,

(SEQ ID NO: 488)

PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,

(SEQ ID NO: 490)

QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,

(SEQ ID NO: 491)

QQFSQPEQEFPQPQQPQQSFPEQQPPF,

(SEQ ID NO: 492)

PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ,

(SEQ ID NO: 493)

SSPLQPEQPFPQQPQQPFPEQPQQPQ,

(SEQ ID NO: 494)

QSIPQPEQPFPQPEQPFPQSQE,

(SEQ ID NO: 495)

PQQPFPQQPQQIIPQ,

(SEQ ID NO: 496)

PQQPIPEQPQPYPEQPQPYPQQ, 

and

(SEQ ID NO: 497)

PQQPFPQPEQPFBQQPQ, 

wherein B represents alpha-aminobutyric acid.

7 . The composition of claim 6 , wherein A comprises an amino acid sequence selected from the group consisting of:

(SEQ ID NO: 486)

QLQPFPQPELPYPQPQLPYPQPQPFR,

(SEQ ID NO: 487)

PQLPYPQPELPYPQPQPFRPEQPYPQPQP,

(SEQ ID NO: 488)

PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL,

(SEQ ID NO: 490)

QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ,

(SEQ ID NO: 491)

QQFSQPEQEFPQPQQPQQSFPEQQPPF,

(SEQ ID NO: 493)

SSPLQPEQPFPQQPQQPFPEQPQQPQ,

(SEQ ID NO: 494)

QSIPQPEQPFPQPEQPFPQSQE,

(SEQ ID NO: 495)

PQQPFPQQPQQIIPQ,

(SEQ ID NO: 496)

PQQPIPEQPQPYPEQPQPYPQQ, 

and

(SEQ ID NO: 497)

PQQPFPQPEQPFBQQPQ, 

wherein B represents alpha-aminobutyric acid.

8 . The composition of claim 6 , wherein the composition comprises twelve unique compounds of Formula (1).

9 . The composition of claim 5 , wherein the composition comprises three or more unique compounds of Formula (1).

10 . The composition of claim 9 , wherein the composition comprises four or more unique compounds of Formula (I).

11 . The composition of claim 10 , wherein the composition comprises five or more unique compounds of Formula (1).

12 . The composition of claim 11 , wherein the composition comprises six or more unique compounds of Formula (1).

13 . The composition of claim 12 , wherein the composition comprises seven or more unique compounds of Formula (1).

14 . The composition of claim 13 , wherein the composition comprises eight or more unique compounds of Formula (1).

15 . The composition of claim 14 , wherein the composition comprises nine or more unique compounds of Formula (1).

16 . The composition of claim 15 , wherein the composition comprises ten or more unique compounds of Formula (1).

17 . The composition of claim 16 , wherein the composition comprises eleven or more unique compounds of Formula (1).

18 . The composition of claim 17 , wherein the composition comprises twelve or more unique compounds of Formula (1).

19 . The composition of claim 5 , wherein the composition comprises:

i) a compound of Formula (1), wherein A is QQPPFSEQEQPVLPQ (SEQ ID NO: 484),

ii) a compound of Formula (1), wherein A is QLQPFPQPELPYPQPQLPYPQPQPFR (SEQ ID NO:486),

iii) a compound of Formula (1), wherein A is PQLPYPQPELPYPQPQPFRPEQPYPQPQP (SEQ ID NO:487),

iv) a compound of Formula (1), wherein A is PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL (SEQ ID NO:488),

v) a compound of Formula (1), wherein A is QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ (SEQ ID NO:490),

vi) a compound of Formula (1), wherein A is QQFSQPEQEFPQPQQPQQSFPEQQPPF (SEQ ID NO:491),

vii) a compound of Formula (1), wherein A is PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ (SEQ ID NO:492),

viii) a compound of Formula (1), wherein A is SSPLQPEQPFPQQPQQPFPEQPQQPQ (SEQ ID NO:493),

ix) a compound of Formula (1), wherein A is QSIPQPEQPFPQPEQPFPQSQE (SEQ ID NO:494),

x) a compound of Formula (1), wherein A is PQQPFPQQPQQIIPQ (SEQ ID NO: 495),

xi) a compound of Formula (1), wherein A is PQQPIPEQPQPYPEQPQPYPQQ (SEQ ID NO: 496), and

xii) a compound of Formula (1), wherein A is PQQPFPQPEQPFBQQPQ, wherein B represents alpha-aminobutyric acid (SEQ ID NO: 497).

20 . The composition of claim 19 , wherein the composition further comprises rapamycin.

21 . A pharmaceutical composition comprising a composition of claim 5 and a pharmaceutically acceptable carrier.

22 . A composition comprising twelve or more peptides selected from:

i) a peptide having the amino acid sequence of QGIIQPEQPAQLEVI (SEQ ID NO: 464),

ii) a peptide having the amino acid sequence of QQPPFSEQEQPVLPQ (SEQ ID NO: 484),

iii) a peptide having the amino acid sequence of QPPFSQQQESPESQQ (SEQ ID NO: 485),

iv) a peptide having the amino acid sequence of QLQPFPQPELPYPQPQLPYPQPQPFR (SEQ ID NO:486),

v) a peptide having the amino acid sequence of PQLPYPQPELPYPQPQPFRPEQPYPQPQP (SEQ ID NO:487),

vi) a peptide having the amino acid sequence of PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL (SEQ ID NO:488),

vii) a peptide having the amino acid sequence of PQQPFPQPEQPFCQQPQ (SEQ ID NO:489),

viii) a peptide having the amino acid sequence of QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ (SEQ ID NO:490),

ix) a peptide having the amino acid sequence of QQFSQPEQEFPQPQQPQQSFPEQQPPF (SEQ ID NO:491),

x) a peptide having the amino acid sequence of PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ (SEQ ID NO:492),

xi) a peptide having the amino acid sequence of SSPLQPEQPFPQQPQQPFPEQPQQPQ (SEQ ID NO:493),

xii) a peptide having the amino acid sequence of QSIPQPEQPFPQPEQPFPQSQE (SEQ ID NO:494),

xiii) a peptide having the amino acid sequence of PQQPFPQQPQQIIPQ (SEQ ID NO: 495),

xiv) a peptide having the amino acid sequence of PQQPIPEQPQPYPEQPQPYPQQ (SEQ ID NO: 496), and

xv) a peptide having the amino acid sequence of PQQPFPQPEQPFBQQPQ, wherein B represents alpha-aminobutyric acid (SEQ ID NO: 497).

23 . The composition of claim 22 , comprising each of the following:

i) a peptide having the amino acid sequence of QQPPFSEQEQPVLPQ (SEQ ID NO: 484),

ii) a peptide having the amino acid sequence of QLQPFPQPELPYPQPQLPYPQPQPFR (SEQ ID NO:486),

iii) a peptide having the amino acid sequence of PQLPYPQPELPYPQPQPFRPEQPYPQPQP (SEQ ID NO:487),

iv) a peptide having the amino acid sequence of PQPQQPEQPFPQPEQEFPQPQQPQQSFPEQQPPL (SEQ ID NO:488),

v) a peptide having the amino acid sequence of QQFLQPEQPFPQQPEQPYPQQPEQPFPQPQQ (SEQ ID NO:490),

vi) a peptide having the amino acid sequence of QQFSQPEQEFPQPQQPQQSFPEQQPPF (SEQ ID NO:491),

vii) a peptide having the amino acid sequence of PTPLQPEQPFPQQPQQPQQPFPQPEQPFPWQPQ (SEQ ID NO:492),

viii) a peptide having the amino acid sequence of SSPLQPEQPFPQQPQQPFPEQPQQPQ (SEQ ID NO:493),

ix) a peptide having the amino acid sequence of QSIPQPEQPFPQPEQPFPQSQE (SEQ ID NO:494),

x) a peptide having the amino acid sequence of PQQPFPQQPQQIIPQ (SEQ ID NO: 495),

xi) a peptide having the amino acid sequence of PQQPIPEQPQPYPEQPQPYPQQ (SEQ ID NO: 496), and

xii) a peptide having the amino acid sequence of PQQPFPQPEQPFBQQPQ, wherein B represents alpha-aminobutyric acid (SEQ ID NO: 497).

24 . The composition of claim 23 , wherein the composition further comprises rapamycin.

25 . A pharmaceutical composition comprising a composition of claim 22 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2025
From: LYNN, GEOFFREY MARTIN; GARLISS, CHRISTOPHER MARTIN O’BRIEN; WELLES, HUGH CLARKE
To: BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC.
Reel/Frame 072380/0433 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2025
From: ISHIZUKA, ANDREW SCOTT
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 072380/0518 →
Continuity (3)
Continuation 18494491 · Oct 25, 2023
Provisional Application 63380931 · Oct 25, 2022
Related Publication 20250242015A1 · Jul 31, 2025
References Cited (302)
US 5312620A · Ribi · 1994 [cited by applicant]
US 6573245B1 · Marciani · 2003 [cited by applicant]
US 6747137B1 · Weinstock et al. · 2004 [cited by applicant]
US 6858396B2 · Dix · 2005 [cited by applicant]
US 9115402B2 · Hacohen et al. · 2015 [cited by applicant]
US 9120841B2 · Hauser et al. · 2015 [cited by applicant]
US 9682934B2 · Stafford et al. · 2017 [cited by applicant]
US 9962453B2 · Georges · 2018 [cited by applicant]
US 11191821B2 · Seder et al. · 2021 [cited by applicant]
US 11723950B2 · Pakyari · 2023 [cited by examiner]
US 20040057958A1 · Waggoner et al. · 2004 [cited by applicant]
US 20060216702A1 · Compans et al. · 2006 [cited by applicant]
US 20080139481A1 · Dix · 2008 [cited by applicant]
US 20080160089A1 · Vitiello et al. · 2008 [cited by applicant]
US 20090048410A1 · Wakefield et al. · 2009 [cited by applicant]
US 20100028381A1 · Gorski et al. · 2010 [cited by applicant]
US 20100129439A1 · Alexis et al. · 2010 [cited by applicant]
US 20110150978A1 · Lee et al. · 2011 [cited by applicant]
US 20120114699A1 · Mistrello et al. · 2012 [cited by applicant]
US 20120141409A1 · Seymour et al. · 2012 [cited by applicant]
US 20130144023A1 · Kim et al. · 2013 [cited by applicant]
US 20130237561A1 · Leoni et al. · 2013 [cited by applicant]
US 20130287857A1 · von Andrian et al. · 2013 [cited by applicant]
US 20130330367A1 · Song et al. · 2013 [cited by applicant]
US 20130336996A1 · Vernejoul et al. · 2013 [cited by applicant]
US 20140037747A1 · Hong et al. · 2014 [cited by applicant]
US 20160310584A1 · Fritsch et al. · 2016 [cited by applicant]
US 20170112923A1 · Seymour et al. · 2017 [cited by applicant]
US 20170224803A1 · Berti et al. · 2017 [cited by applicant]
US 20170304420A1 · Fisher et al. · 2017 [cited by applicant]
US 20170348430A1 · Amir et al. · 2017 [cited by applicant]
US 20180221277A1 · Hong et al. · 2018 [cited by applicant]
US 20190060435A1 · Seder et al. · 2019 [cited by applicant]
US 20190070233A1 · Yeung et al. · 2019 [cited by applicant]
US 20200009069A1 · Luo et al. · 2020 [cited by applicant]
US 20200054741A1 · Lynn et al. · 2020 [cited by applicant]
US 20210000934A1 · Fisher et al. · 2021 [cited by applicant]
US 20210113705A1 · Lynn et al. · 2021 [cited by applicant]
US 20210393523A1 · Lynn et al. · 2021 [cited by applicant]
US 20220152170A1 · Seder et al. · 2022 [cited by applicant]
US 20220305099A1 · Stojdl et al. · 2022 [cited by applicant]
US 20230381112A1 · Lynn et al. · 2023 [cited by applicant]
US 20240269269A1 · Lynn et al. · 2024 [cited by applicant]
US 20240382614A1 · Lynn et al. · 2024 [cited by applicant]
US 20250090658A1 · Fisher et al. · 2025 [cited by applicant]
CA 2627903A1 · 2009 [cited by applicant]
CN 101684174B · 2012 [cited by applicant]
CN 113214171A · 2021 [cited by applicant]
EP 0324455A2 · 1989 [cited by applicant]
EP 2958994B1 · 2019 [cited by applicant]
JP 2001294636A · 2001 [cited by applicant]
JP 2014139139A · 2014 [cited by applicant]
KR 20090002946A · 2009 [cited by applicant]
WO WO1993022338A1 · 1993 [cited by applicant]
WO WO1996015249A1 · 1996 [cited by applicant]
WO WO1998001558A2 · 1998 [cited by applicant]
WO WO1998019710A2 · 1998 [cited by applicant]
WO WO2000016746A2 · 2000 [cited by applicant]
WO WO2000074722A2 · 2000 [cited by applicant]
WO WO2001018035A2 · 2001 [cited by applicant]
WO WO2001052614A2 · 2001 [cited by applicant]
WO WO2002070006A2 · 2002 [cited by applicant]
WO WO2002094994A2 · 2002 [cited by applicant]
WO WO2003075956A2 · 2003 [cited by applicant]
WO WO2004007525A3 · 2004 [cited by applicant]
WO WO2005007789A2 · 2005 [cited by applicant]
WO WO2005099752A2 · 2005 [cited by applicant]
WO WO2006083874A2 · 2006 [cited by applicant]
WO WO2006084319A1 · 2006 [cited by applicant]
WO WO2007075502A2 · 2007 [cited by applicant]
WO WO2004071457A3 · 2007 [cited by applicant]
WO WO2007149802A2 · 2007 [cited by applicant]
WO WO2009043165A1 · 2009 [cited by applicant]
WO WO2009051837A2 · 2009 [cited by applicant]
WO WO2009104001A2 · 2009 [cited by applicant]
WO WO2010067041A1 · 2010 [cited by applicant]
WO WO2010128303A1 · 2010 [cited by applicant]
WO WO2011101332A1 · 2011 [cited by applicant]
WO WO2011150240A1 · 2011 [cited by applicant]
WO WO2012041669A1 · 2012 [cited by applicant]
WO WO2012049317A3 · 2012 [cited by applicant]
WO WO2012090002A1 · 2012 [cited by applicant]
WO WO2012139094A3 · 2012 [cited by applicant]
WO WO2013006050A9 · 2013 [cited by applicant]
WO WO2013019669A2 · 2013 [cited by applicant]
WO WO2013080187A1 · 2013 [cited by applicant]
WO WO2013051936A9 · 2013 [cited by applicant]
WO WO2013151771A1 · 2013 [cited by applicant]
WO WO2013154774A1 · 2013 [cited by applicant]
WO WO2014142653A1 · 2014 [cited by applicant]
WO WO2015033140A1 · 2015 [cited by applicant]
WO WO2015082905A1 · 2015 [cited by applicant]
WO WO2015085233A1 · 2015 [cited by applicant]
WO WO2016043620A1 · 2016 [cited by applicant]
WO WO2016055812A1 · 2016 [cited by applicant]
WO WO2016146143A1 · 2016 [cited by applicant]
WO WO2016146260A1 · 2016 [cited by applicant]
WO WO2017044803A1 · 2017 [cited by applicant]
WO WO2017083963A1 · 2017 [cited by applicant]
WO WO2017147597A1 · 2017 [cited by applicant]
WO WO2017157964A1 · 2017 [cited by applicant]
WO WO2017173321A1 · 2017 [cited by applicant]
WO WO2018055060A1 · 2018 [cited by applicant]
WO WO2018059896A1 · 2018 [cited by applicant]
WO WO2018148671A1 · 2018 [cited by applicant]
WO WO2018187356A2 · 2018 [cited by applicant]
WO WO2018187515A1 · 2018 [cited by applicant]
WO WO2019094642A1 · 2019 [cited by applicant]
WO WO2019126186A1 · 2019 [cited by applicant]
WO WO2019126371A1 · 2019 [cited by applicant]
WO WO2019134049A1 · 2019 [cited by applicant]
WO WO2019195626A1 · 2019 [cited by applicant]
WO WO2019204663A1 · 2019 [cited by applicant]
WO WO2019226828A2 · 2019 [cited by applicant]
WO WO2019241306A2 · 2019 [cited by applicant]
WO WO2019246315A1 · 2019 [cited by applicant]
WO WO2020072681A1 · 2020 [cited by applicant]
WO WO2020190762A1 · 2020 [cited by applicant]
WO WO2020191305A3 · 2020 [cited by applicant]
WO WO2020231274A1 · 2020 [cited by applicant]
WO WO2021041518A2 · 2021 [cited by applicant]
WO WO2021156404A3 · 2021 [cited by applicant]
WO WO2022066635A1 · 2022 [cited by applicant]
WO WO2022086853A1 · 2022 [cited by applicant]
WO WO2022177993A1 · 2022 [cited by applicant]
WO WO2022266340A1 · 2022 [cited by applicant]
WO WO2024092030A1 · 2024 [cited by applicant]
WO WO2024092028A3 · 2024 [cited by applicant]
Accardo et al. Self-assembled or mixed peptide amphiphile micelles from Herpes simplex virus glycoproteins as potential immunomodulatory treatment. Int J Nanomedicine. 2014;9:2137-2148. [cited by applicant]
Acrylamide, retrieved from <https://en.wikipedia.org/wiki/Acrylamide> on Jun. 4, 2016. [cited by applicant]
Adjuvant Therapy, retrieved from <http://en.wikipedia.org/wiki/Adjuvant_therapy> on May 28, 2012. [cited by applicant]
Adjuvant, retrieved from <http://en.wikipedia.org/wiki/Adjuvant> on May 9, 2012. [cited by applicant]
Amino Acid Structures, Codes, and Reference Information, retrieved from <www.promega.com/resources/tools/amino-acid-chart-amino-acid-structure> on Apr. 21, 2022. [cited by applicant]
Amino Acids Molecular Weights, retrieved from <http://fortiusbio.com/Aa_MW.html> on Dec. 22, 2021. [cited by applicant]
Arnon et al. Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A. 1980;77(11):6769-6772. [cited by applicant]
Atherton et al. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer. Vaccine. 2018;36(16):2181-2192. [cited by applicant]
Audibert et al. Successful immunization with a totally synthetic diphtheria vaccine. Proc Natl Acad Sci U S A. 1982;79(16):5042-5046. [cited by applicant]
Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-796. [cited by applicant]
Baharom et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat Immunol. 2021;22(1):41-52. [cited by applicant]
Barrios & Celis. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother. 2012;61(8):1307-1317. [cited by applicant]
Başalp et al. Immune response to 17beta-estradiol involved in polymer gels: antigen specificity and affinity of hybridoma clones. Hybridoma. 2000;19(6):495-499. [cited by applicant]
Belnoue et al. Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Mol Ther. 2016;24(9):1675-1685. [cited by applicant]
Belnoue et al. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. JCI Insight. 2019;5(11):e127305. [cited by applicant]
Bissett et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J Cancer. 2004;91(1):50-55. [cited by applicant]
Black et al. Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater. 2012;24(28):3845-3849. [cited by applicant]
Bogyo et al. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol. 1998;5(6):307-320. [cited by applicant]
Brito & O'Hagan. Designing and building the next generation of improved vaccine adjuvants. J Control Release. 2014;190:563-579. [cited by applicant]
Cabral et al. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release. 2007;121(3):146-155. [cited by applicant]
Carr et al. Complexation Hydrogels for the Oral Delivery of Growth Hormone and Salmon Calcitonin. Ind Eng Chem Res. 2010;49(23):11991-11995. [cited by applicant]
CD40 (Protein), retrieved at <https://en.wikipedia.org/w/index.php?title=CD40_(protein)&oldid=742991040>. [cited by applicant]
Chan et al. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem. 2009;20(6):1194-1200. [cited by applicant]
Chaudhuri et al. High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. AAPS J. 2014;16(1):48-64. [cited by applicant]
Chedid et al. Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)—poly(L-lysine) carrier. Proc Natl Acad Sci U S A. 1979;76(12):6557-6561. [cited by applicant]
Chemistry of Crosslinking, retrieved at <www.thermofisher.com/us/en/home/life-science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/chemistry-crosslinking.html> … [cited by applicant]
ChitoClear—A Natural and Functional Ingredient for Personal Care Products & LipoSan—The Natural Way of Weight Loss, retrieved at <http://www.primex.is/Products> (2013). [cited by applicant]
Chitosan, retrieved at <http://en.wikipedia.org/wiki/Chitosan> on Aug. 29, 2014. [cited by applicant]
Cho et al. BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother. 2013;62(4):787-799. [cited by applicant]
Choe Y et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem. 2006;281(18):12824-12832. [cited by applicant]
Chruszcz et al. Serum albumins-unusual allergens. Biochim Biophys Acta. 2013;1830(12):5375-5381. [cited by applicant]
Collins et al. Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol. ACS Nano. 2010;4(5):2856-2864. [cited by applicant]
Co-pending U.S. Appl. No. 18/277,220, filed Aug. 14, 2023. [cited by applicant]
Cristofaro & Opal. The Toll-like receptors and their role in septic shock. Expert Opin Ther Targets. 2003;7(5):603-612. [cited by applicant]
Dane et al. Big thinking for adjuvants. Nat Biotechnol. 2015;33(11):1146-1148. [cited by applicant]
Dehsorkhi et al. Self-assembling amphiphilic peptides. J Pept Sci. 2014;20(7):453-467. [cited by applicant]
Dintzis et al. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci U S A. 1976;73(10):3671-3675. [cited by applicant]
DNA methyltransferase [Brachyspira hyodysenteriae]—NCBI Reference Sequence: WP_047111413.1, NCBI Protein Database <https://www.ncbi.nlm.nih.gov>, earliest reference of 1986, accessed Oct. 12, 2023. [cited by applicant]
Du et al. Paclitaxel-loaded micelles composed of folate-poly(ethylene glycol) and poly(gamma-benzyl l-glutamate) diblock copolymer. Colloid Surf A. 2010;353:140-148. [cited by applicant]
Duncan & Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev. 2010;62(2):272-282. [cited by applicant]
Duncan et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer. 1988;57(2):147-156. [cited by applicant]
Duong et al. Pronounced peptide selectivity for melanoma through tryptophan end-tagging. Sci Rep. 2016;6:24952. [cited by applicant]
Ekladious et al. Polymer-drug conjugate therapeutics: advances, insights and prospects. Nat Rev Drug Discov. 2019;18(4):273-294. [cited by applicant]
Etrych et al. Synthesis of HPMA Copolymers Containing Doxorubicin Bound via a Hydrazone Linkage. Effect of Spacer on Drug Release and in vitro Cytotoxicity. Macromol. Biosci. 2002;2(1):43-52. [cited by applicant]
Feng et al. Polymeric Conjugates for Anti-Cancer Drug Delivery. Literature Seminar. 2010. [cited by applicant]
Fexby & Bülow. Hydrophobic peptide tags as tools in bioseparation. Trends Biotechnol. 2004;22(10):511-516. [cited by applicant]
Francica et al. Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjug Chem. 2016;27(10):2372-2385. [cited by applicant]
Fujita et al. 6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine. Amino Acids. 2016;48(5):1319-1329. [cited by applicant]
Fuks et al. Biohybrid block copolymers: towards functional micelles and vesicles. Chem Soc Rev. 2011;40(5):2475-2493. [cited by applicant]
Gerster et al. Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J Med Chem. 2005;48(10):3481-3491. [cited by applicant]
Ghendon et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol. 2008;153(5):831-837. [cited by applicant]
Golovanov et al. A simple method for improving protein solubility and long-term stability. J Am Chem Soc. 2004;126(29):8933-8939. [cited by applicant]
Greco & Vicent. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61(13):1203-1213. [cited by applicant]
Grela et al. The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J Immunol. 2011; 186(1):284-290.). [cited by applicant]
Guidelines on Adjuvants in Vaccines for Human Use, EMEA Adjuvants Guidance, The European Medicines Agency Evaluation of Medicines for Human Use (2005). [cited by applicant]
Guo et al. Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep. 2016;4(5):528-534. [cited by applicant]
Gutjahr et al. Triggering Intracellular Receptors for Vaccine Adjuvantation [published correction appears in Trends Immunol. Oct. 2016;37(10):716. [cited by applicant]
Hamaguchi et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92(7):1240-1246. [cited by applicant]
Harris et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci U S A. 2000;97(14):7754-7759. [cited by applicant]
Harris et al. Substrate specificity of the human proteasome. Chem Biol. 2001;8(12):1131-1141. [cited by applicant]
Hein et al. Click Chemistry, A Powerful Tool for Pharmaceutical Sciences. Pharmaceutical Research. 2008; 25(10):2216-2230. [cited by applicant]
Heuking & Borchard. Toll-like receptor-7 agonist decoration enhances the adjuvanticity of chitosan-DNA nanoparticles. J Pharm Sci. 2012;101(3):1166-1177. [cited by applicant]
Heuking et al. Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J Drug Target. 2009;17(8):662-670. [cited by applicant]
Heuking et al. Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination. Int J Pharm. 2009;381(2):97-105. [cited by applicant]
How to Enhance the Solubility of L-Tyrosine in Cell Culture Media Applications, retrieved from <https://healthcare.evonik.com/en/biopharma/cell-culture/common-challenges/performance-improvement> on Dec. 1, 2022. [cited by applicant]
Huber et al. Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity. Cell. 2012;148(4):727-738. [cited by applicant]
Seder et al., U.S. Appl. No. 16/079,972, filed Aug. 24, 2018. [cited by applicant]
International Preliminary Examination Report dated Sep. 13, 2011 and received in PCT/GB2010/000915, 19 pages. [cited by applicant]
International Search Report and Written Opinion dated Aug. 19, 2010and received in PCT/GB2010/000915, 14 pages. [cited by applicant]
International Search Report and Written Opinion dated Dec. 14, 2015 and received in PCT/GB2015/052974, 13 pages. [cited by applicant]
International Search Report and Written Opinion dated Dec. 5, 2019 and received in PCT/US2019/033612, 23 pages. [cited by applicant]
International Search Report and Written Opinion dated Feb. 20, 2024 and received in PCT/US2023/077767, 19 pages. [cited by applicant]
International Search Report and Written Opinion dated Jan. 25, 2022 and received in PCT/US2021/051298, 15 pages. [cited by applicant]
International Search Report and Written Opinion dated Jan. 6, 2020 and received in PCT/US2019/054343, 13 pages. [cited by applicant]
International Search Report and Written Opinion dated Jun. 17, 2024 and received in PCT/US2023/077765, 11 pages. [cited by applicant]
International Search Report and Written Opinion dated Mar. 1, 2021 and received in PCT/US2020/047962, 16 pages. [cited by applicant]
International Search Report and Written Opinion dated May 8, 2022 and received in PCT/US2022/016600, 26 pages. [cited by applicant]
International Search Report and Written Opinion dated Sep. 24, 2018 and received in PCT/US2018/026145, 13 pages. [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/US2022/033819, dated Sep. 13, 2022. [cited by applicant]
Iurovskiǐ et al. [Artificial peptide and carbohydrate antigens. Immobilization of haptens and adjuvant (MDP) on polyacrylamide]. Abstract. Bioorg Khim. 1986;12(1):100-105. [cited by applicant]
Jackson DC, Lau YF, Le T, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2004;… [cited by applicant]
Ji & Feng. Solubility of amino acids in water and aqueous solutions by the statistical associating fluid theory. Ind. Eng. Chem. Res. 2008;47(16):6275-6279. [cited by applicant]
Joshi et al. Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor. Immunity. 2007;27(2):281-295. [cited by applicant]
Kim et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10(11):3708-3716. [cited by applicant]
Klein et al. Design and characterization of structured protein linkers with differing flexibilities. Prot. Eng. Des. Selection. 2014; 27:325-330. [cited by applicant]
Kleine et al. Lipopeptide-polyoxyethylene conjugates as mitogens and adjuvants. Immunobiology. 1994;190(1-2):53-66. [cited by applicant]
Levina et al. Synthesis of polyamine-containing oligonucleotides. Russ. J. Bioorg. Chem. 2008;34(1):89-95. [cited by applicant]
Liras et al. Thermo-responsive allyl-f2-(2-methoxyethoxy)ethyl methacrylate-based polymers as versatile precursors for smart polymer conjugates and conetworks. Macromolecules. 2011;44(10):3739-3745. [cited by applicant]
Liu et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519-522; Supplementary Information pp. 1-9. [cited by applicant]
Luo et al. Synthetic nanovaccines for immunotherapy. J Control Release. 2017;263:200-210. [cited by applicant]
Lynn et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol. 2015;33(11):1201-1210; Supplementary Figures 1-15; Supplementary… [cited by applicant]
Lynn et al. Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines. Cancer Lett. 2019;459:192-203. [cited by applicant]
Lynn et al. Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat Biotechnol. 2020;38(3):320-332. [cited by applicant]
Lynn t al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol. 2015;33(11):1201-1210. [cited by applicant]
MacKay et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater. 2009;8(12):993-999. [cited by applicant]
Maurer et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol. 2002;32(8):2356-2364. [cited by applicant]
McGray et al. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. J Immunother Cancer. 2019;… [cited by applicant]
Meerum Terwogt et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001;12(4):315-323. [cited by applicant]
Methacrylamide, retrieved from <https://en.wikipedia.org/wiki/Methacrylamide> on Jun. 4, 2016. [cited by applicant]
Mitsui et al. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol. 2006;126(8):1804-1812. [cited by applicant]
Morgan et al. Evaluation of N-(2-hydroxypropyl)methacrylamide copolymer-peptide conjugates as potential oral vaccines. Studies on their degradation by isolated rat small intestinal peptidases and their uptake by adult r… [cited by applicant]
Moyle & Toth. Self-adjuvanting lipopeptide vaccines. Curr Med Chem. 2008;15(5):506-516. [cited by applicant]
Moynihan et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22(12):1402-1410. [cited by applicant]
Oh, et al., “pH-sensitive properties of surface charge-switched multifunctional polymeric micelle”, Int J Pharm, Jul. 2009, vol. 376(1-2): pp. 134-140. Epub Apr. 24, 2009. doi: 10.1016/j.ijpharm.2009.04.021. [cited by applicant]
Orädd et al. Effects of peptide hydrophobicity on its incorporation in phospholipid membranes—an NMR and ellipsometry study. Biochim Biophys Acta. 2011;1808(1):244-252. [cited by applicant]
P04141—CSF2_Human—Granulocyte-Macrophage Colony-Stimulating Factor Precursor—CSF2, retrieved at <http://www.uniprot.org/uniprot/P04141>. [cited by applicant]
P23510—TNFL4_Human—Tumor Necrosis Factor Ligand Superfamily Member 4 - TNFSF4, retrieved from <http://www.uniprot.org/uniprot/P23510>. [cited by applicant]
P25942—TNR5_Human—Tumor necrosis factor receptor superfamily member 5—CD40, retrieved at <http://www.uniprot.org/uniprot/P25942>. [cited by applicant]
Particulate Contamination—Risk Prevention in Infusion Therapy, B. Braun Melsungen AG, No. 6069091, Edition: 03, 2011. [cited by applicant]
Pelin, Bio-engineering vaccinia viruses for increased oncolytic potential, University of Ottawa, Dec. 2, 2019, retrieved from <http://hdl.handle.net/10393/39909> on Jun. 28, 2022. [cited by applicant]
Pentadecane, retrieved at <https://pubchem.ncbi.nlm.nih.gov/compound/Pentadecane> on Oct. 12, 2023. [cited by applicant]
Peptide Mimetics, retrieved at <www.biosyn.com/tew/peptide-mimetics.aspx> (2012). [cited by applicant]
Perrie et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm. 2008;364(2):272-280. [cited by applicant]
Petho et al. Amphiphilic drug-peptide-polymer conjugates based on poly(ethylene glycol) and hyperbranched polyglycerol for epidermal growth factor receptor targeting: the effect of conjugate aggregation on in vitro acti… [cited by applicant]
Pina et al. Tryptophan tags and de novo designed complementary affinity ligands for the expression and purification of recombinant proteins. J Chromatogr A. 2016;1472:55-65. [cited by applicant]
Pol et al. Development and applications of oncolytic Maraba virus vaccines. Oncolytic Virother. 2018;7:117-128. [cited by applicant]
Pola et al. Click chemistry as a powerful and chemoselective tool for the attachment of targeting ligands to polymer drug carriers. Polym. Chem. 2014;5(4):1340-1350. [cited by applicant]
Polyacrylamide, retrieved at <https://en.wikipedia.org/wiki/Polyacrylamide> on Jun. 4, 2016. [cited by applicant]
Raissi et al. Enhanced potency of the metalloprotease inhibitor TAPI-2 by multivalent display. Bioorg Med Chem Lett. 2014;24(8):2002-2007. [cited by applicant]
Ríhová et al. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility. Ann N Y Acad Sci. 1997;831:57-71. [cited by applicant]
Rowe, Validating transgenic Farmington viruses for the treatment of glioblastoma multiforme, University of Ottawa, Jan. 1, 2015, retrieved from <http://hdl.handle.net/10393/33354> on Nov. 19, 2019. [cited by applicant]
Ryu et al. Stimulation of innate immune cells by light-activated TLR7/8 agonists. J Am Chem Soc. 2014;136(31):10823-10825. [cited by applicant]
Sainz et al. Alpha-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma. Acta Biomater. 2018;76:193-207. [cited by applicant]
Segura & Hubbell. Synthesis and in vitro characterization of an ABC triblock copolymer for siRNA delivery. Bioconjug Chem. 2007;18(3):736-745. [cited by applicant]
Seymour et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20(6):1668-1676. [cited by applicant]
Seymour et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009;34(6):1629-1636. [cited by applicant]
Shakya et al. Characterization of chemically defined poly-N-isopropylacrylamide based copolymeric adjuvants. Vaccine. 2013;31(35):3519-3527. [cited by applicant]
Shi et al. Novel vaccine adjuvant LPS-Hydrogel for truncated basic fibroblast growth factor to induce antitumor immunity. Carbohydr Polym. 2012;89(4):1101-1109. [cited by applicant]
Shukla et al. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. Bioorg Med Chem Lett. 2011;21(11):3232-3236. [cited by applicant]
Speir et al. Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins. Sci Rep. 2017;7(1):14273. [cited by applicant]
Subr et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. J Control Release. 2009;135(2):152-158. [cited by applicant]
Tanji et al. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science. 2013;339(6126):1426-1429. [cited by applicant]
TentaGel® PAP TentaGel resins for the synthesis of PEG attached peptides, Rapp Polymere, retrieved from http://www.rapp-polymere.com/index.php?id=936. [cited by applicant]
Toll-Like Receptor, retrieved from <http://en.wikipedia.org/wiki/Toll-like_receptor> on May 28, 2012. [cited by applicant]
Tom et al. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends Biotechnol. 2019;37(4):373-388. [cited by applicant]
Trent et al. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination. AAPS J. 2015;17(2):380-388. [cited by applicant]
Trzcinska et al. Bioactive mesoglobules of poly(di(ethylene glycol) monomethyl ether methacrylate)-peptide conjugate. Polym. Chem. 2012;50(15):3104-3115. [cited by applicant]
Tyrosine Y (Tyr), retrieved from http://www.biology.arizona.edu/biochemistry/problem_sets/aa/tyrosine.html (2003). [cited by applicant]
Tyrosine, retrieved from <www.russelllab.org/aas/Tyr.html#:-:text=Substitutions%3A%20As%20Tyrosine%20is%20an,position%20on%20the%20benzene%20ring> on Apr. 21, 2022. [cited by applicant]
Wagner & Musso. New naturally occurring amino acids. Angew. Chem. Int. 1983;22:816-828. [cited by applicant]
Wang & Roberts (Ed.). Aggregation of therapeutic proteins passage. 5.3.6 Turbidimetry and Nephelometry (pp. 235-237), p. 236, second and third paragraphs (2010). [cited by applicant]
Water Absorption (How Much Water Gets Soaked Up)—The Percentage Increase in Weight of a Plastic Article When Immersed in Water for a Specified Time and at a Specified Temperature, Properties—Water Absorption, www. curbe… [cited by applicant]
Weterings et al. Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines. Bioorg Med Chem Lett. 2006;16(12):3258-3261. [cited by applicant]
Wille-Reece et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A. 2005;102(42):15190-15… [cited by applicant]
Wille-Reece et al. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol. 2005;174(12):7676-7683. [cited by applicant]
Wille-Reece et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med. 2006;203(5):1249-1258. [cited by applicant]
Wilson et al. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013;7(5):3912-3925. [cited by applicant]
Wu et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A. 2007;104(10):3990-3995. [cited by applicant]
Wu. Strategies for designing synthetic immune agonists. Immunology. 2016;148(4):315-325. [cited by applicant]
Yadav et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572-576. [cited by applicant]
Zeng et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J Biol Chem. 2011;286(15):12944-12951. [cited by applicant]
Zhang et al. Tunable diblock copolypeptide hydrogel depots for local delivery of hydrophobic molecules in healthy and injured central nervous system. Biomaterials. 2014;35(6):1989-2000. [cited by applicant]
Zhu et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017;8(1):1954. [cited by applicant]
Zom et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res. 2014;2(8):756-764. [cited by applicant]
U.S. Appl. No. 13/318,844, filed Feb. 21, 2012, Multi-Valent Adjuvant Display, Abandoned. [cited by applicant]
U.S. Appl. No. 15/299,936, filed Oct. 21, 2016, Multi-Valent Adjuvant Display, Abandoned. [cited by applicant]
U.S. Appl. No. 15/517,121, filed Apr. 5, 2017, Polymer Adjuvant, Abandoned. [cited by applicant]
U.S. Appl. No. 16/907,912, filed Jun. 22, 2020, Polymer Adjuvant, Abandoned. [cited by applicant]
U.S. Appl. No. 18/970,451, filed Dec. 5, 2024, Polymer Adjuvant, Pending. [cited by applicant]
U.S. Appl. No. 16/500,762, filed Oct. 3, 2019, Peptide-Based Vaccines, Methods of Manufacturing, and Uses Thereof for Inducing an Immune Response, Published as US 2020-0054741 A1. [cited by applicant]
U.S. Appl. No. 17/057,658, filed Nov. 21, 2020, Improved Methods of Manufacturing Peptide-Based Vaccines, Published as US 2021/0113705 A1. [cited by applicant]
U.S. Appl. No. 17/282,447, filed Apr. 2, 2021, Aromatic Ring Substituted Amphiphilic Polymers as Drug Delivery Systems, Published as US 2021/0393523 A1. [cited by applicant]
U.S. Appl. No. 17/604,227, filed Oct. 15, 2021, Compositions and Methods of Manufacturing Star Polymers for Ligand Display and/or Drug Delivery, Pulished as US 2023/0026627 A1. [cited by applicant]
U.S. Appl. No. 18/277,220, filed Aug. 14, 2023, Self-Assembling Nanoparticles Based on Amphiphilic Peptides, Pending. [cited by applicant]
U.S. Appl. No. 18/570,579, filed Dec. 14, 2023, Self-Assembling Nanoparticles Based on Amphiphilic Peptides for Drug Delivery Applications, Published as US 2024/0382614 A1. [cited by applicant]
U.S. Appl. No. 18/027,346, filed Mar. 20, 2023, Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ, Published as US 2023/0381112 A1. [cited by applicant]
U.S. Appl. No. 18/032,538, filed Apr. 18, 2023, Star Polymer Drug Conjugates, Published as US 2023/0390406 A1. [cited by applicant]
U.S. Appl. No. 17/638,576, filed Feb. 25, 2022, Methods for Inducing An Immune Response Against Neoantigens, Published as US 202210305099 A1. [cited by applicant]
U.S. Appl. No. 18/494,491, filed Oct. 25, 2023, Self-Assembling Nanoparticles, Published as US 2024/0269269 A1. [cited by applicant]
Fuks et al., Biohybrid block copolymers: towards functional micelles and vesicles, Chem. Soc. Rev., 40:2475-2493 (2011). [cited by applicant]
Komatsu et al., Facile preparation of degradable thermoresponsive polymers as biomaterials, Polymer 130:68-73 (2017). [cited by applicant]
Co-Pending U.S. Appl. No. 19/242,746, filed Jun. 18, 2025. [cited by applicant]
Co-Pending U.S. Appl. No. 19/246,539, filed Jun. 23, 2025. [cited by applicant]
Co-Pending U.S. Appl. No. 19/183,635, filed Apr. 18, 2025. [cited by applicant]